70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo

Wayne Kuznar
Published Online: Monday, Apr 18, 2016

Because nearly all ER-negative or HER2-postive tumors would be expected to rate as both clinically and genomically high risk, MammaPrint and the MINDACT results bear mostly on the heterogeneity within ER-positive, HER2-negative cancers, commented Harold Burstein, MD, PhD, clinical oncologist at Dana-Farber Cancer Institute, Boston.

The study “confirms the primary hypothesis that integration of genomic signature permits identification of a cohort of ER-positive tumors with good prognosis with endocrine therapy alone, regardless of larger T stage and N1 status,” he said, advocating that most ER-positive, HER2-negative stage 1 and 2 cancers, including N1, warrant tumor genomic profiling for optimal adjuvant decision-making.
Piccart M, Rutgers E, van’t Veer L, et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Presented at: AACR Annual Meeting 2016, New Orleans; April 16-20, 2016. Abstract CT-039.

<<< View more from the 2016 AACR Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x